Results 181 to 190 of about 161,535 (242)

Co-immunization with spike and nucleocapsid based DNA vaccines for long-term protective immunity against SARS-CoV-2 Omicron. [PDF]

open access: yesNPJ Vaccines
Pinto PBA   +17 more
europepmc   +1 more source

Status and future of recombinant adeno‐associated virus vector manufacturing

open access: yesBiotechnology Progress, EarlyView.
Abstract Sixty years of adeno‐associated virus (AAV) research illustrates a trajectory marked by basic science exploration, iterative innovation, persistent challenges, a number of clinical setbacks, as well as commercial therapeutic triumphs. This continual evolution has led to recombinant AAV (rAAV) becoming a cornerstone of modern gene therapy ...
Frank Agbogbo, David Dismuke
wiley   +1 more source

Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients. [PDF]

open access: yesGenome Med
Zhang X   +32 more
europepmc   +1 more source

Viscosity of concentrated mRNA solutions: Implications for downstream processing

open access: yesBiotechnology Progress, EarlyView.
Abstract Messenger RNA (mRNA) therapeutics can be used to protect against infectious disease and for the treatment of cancers and genetic disorders. In order to obtain the desired therapeutic dosage, it is necessary to concentrate the mRNA to levels where the viscosity of the mRNA solutions can become significant.
Amin Javidanbardan   +3 more
wiley   +1 more source

Screening of bispecific antibodies during single cell cloning of recombinant Chinese hamster ovary cell lines to improve titer and product quality

open access: yesBiotechnology Progress, EarlyView.
Abstract Development of therapeutic bispecific antibodies (BsAbs) poses significant manufacturability challenges associated with correct chain pairing and an increased diversity of impurities. Here we address this with a product quality assessment during cell line development (CLD), forgoing the need for genetic characterization during cell line ...
Molly Robinson   +7 more
wiley   +1 more source

Demonstration of nanofiltration‐based virus safety for AAV manufacturing using model viruses

open access: yesBiotechnology Progress, EarlyView.
Abstract Virus safety for biopharmaceutical products has been a well‐established concern for several decades. While various virus reduction steps have been identified and implemented for traditional plasma‐derived and monoclonal antibody products, there are various challenges to achieving the same virus safety in emerging gene therapy products.
Brian Buesing   +2 more
wiley   +1 more source

Fungal Antimicrobial Resistance: Mechanisms, Drivers, and Global Clinical Burden

open access: yesChemFoodChem, EarlyView.
ABSTRACT Fungal antimicrobial resistance (AMR) is a growing concern for world health caused by an increase in multidrug‐resistant infections, an increase in environmental reservoirs, and the ineffectiveness of current antifungal treatments. Fungal infections continue to be largely excluded from AMR initiatives while causing over 1.6 million deaths ...
Bikash Baral
wiley   +1 more source

Membrane‐Permeable Nucleoside T‐1106 Diphosphate and Triphosphate Analogues as Antiviral Pronucleotides

open access: yesChemistry – A European Journal, EarlyView.
Favipiravir (T‐705) and the non‐fluorinated counterpart (T‐1106) are antiviral agents that inhibit the RNA‐dependent RNA polymerase (RdRp) of various RNA viruses. The antiviral efficacy of nucleoside analogues is strongly dependent on their intracellular activation by cellular kinases to produce their corresponding triphosphate metabolites (T‐705‐RTP ...
Chris Meier   +7 more
wiley   +1 more source

DNA Vaccines Encoding HTNV GP-Derived Th Epitopes Benefited from a LAMP-Targeting Strategy and Established Cellular Immunoprotection. [PDF]

open access: yesVaccines (Basel)
Jiang D   +23 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy